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Abstract
Cardiomyopathy includes a diverse and heterogeneous group of disorders 
affecting the myocardium and eventually leading to cardiac dysfunction. 
Cardiomyopathy is the leading cause of hospitalization in patients older than 
65 years of age and it is an important cause for enormous healthcare expenditure. 
All reversible cardiomyopathies can be associated with cardiomegaly, systolic heart 
failure, structural changes, and an increase in mortality, but when the offensive 
agent is identified and stopped, these conditions tend to stop their progression and 
reverse. The prognosis of reversible nonischemic cardiomyopathies is better than 
ischemic or other nonreversible cardiomyopathies. Additionally, it is important to 
diagnose etiology of HF early and precisely to determine prognosis and effective 
treatment. Most patients with reversible cardiomyopathy present with clinical 
picture similar to that of systolic heart failure. Here in this book chapter, we discuss 
about different types of reversible cardiomyopathy including pathogenesis, clinical 
picture, diagnosis and treatment.
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1. Introduction
The heart is composed of a special tissue and a unique electrical system. Though 
there are some hypotheses about the possibility of regeneration, the cardiac tissue is 
composed of non-regenerative muscle cells called myocytes which have the capac-
ity to revert acute damages before necrosis and subsequent fibrosis are present. 
It is thought that this reversion could be related to multiple factors. A decrease in 
inflammatory markers, perfusion recovery, and possible RNA reactions reduce 
the fiber tension and inflammation that cause the shortening of the dilated fibers, 
and then the transient condition will improve. All reversible cardiomyopathies can 
be associated with cardiomegaly, systolic heart failure, structural changes, and an 
increase in mortality, but when the offensive agent is identified and stopped, these 
conditions tend to stop their progression and reverse. In a period of 6 weeks, we are 
usually able to evaluate positive results after the stunning myocardial cells recover. 
Most patients with reversible cardiomyopathy present with clinical picture similar 
to that of systolic heart failure (HF) as follows:
• Dyspnea
• Chest discomfort/pain
• Lower extremity edema or peripheral edema
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• Weight gain
• Orthopnea or paroxysmal nocturnal dyspnea (PND)
• Decrease in exercise tolerance etc.
In this chapter, we have focused on important types of reversible cardiomy-
opathy (Figure 1).
2. Epidemiology
Cardiomyopathy includes a diverse and heterogeneous group of disorders affect-
ing the myocardium and eventually leading to cardiac dysfunction. [1] The HF is a 
widely prevalent syndrome today and affects 5.1 million adult Americans over the 
age of 20. [1] Cardiomyopathy is the leading cause of hospitalization in patients 
older than 65 years of age and it is an important cause for enormous healthcare 
expenditure. Interestingly, ischemic cardiomyopathy is responsible for about half of 
these patients. On the other hand, the prevalence of reversible nonischemic car-
diomyopathy is also significant, as per several large clinical trials, and ranges from 
20–50%. [1] The prognosis of reversible nonischemic cardiomyopathies is better 
than ischemic or other nonreversible cardiomyopathies which were suggested by 
the epidemiological evidence [1]. Additionally, it is important to diagnose etiology 
of HF early and precisely to determine prognosis and effective treatment.
Figure 1. 





Arrhythmia-induced cardiomyopathy (also known as tachycardia-induced 
cardiomyopathy, tachycardia-mediated cardiomyopathy, or tachymyopathy) is one 
of the reversible causes of dilated cardiomyopathy. Arrhythmia-induced cardiomy-
opathy is defined by the presence of a sustained tachycardia (or frequent episodes of 
tachycardia or very frequent ectopy) which results in left ventricular (LV) systolic 
dysfunction. It is a relatively rare, but well-recognized entity caused by long-stand-
ing tachycardia, which can be treated readily in most instances and have a good 
prognosis. A common clinical problem is differentiating whether tachycardia is the 
primary cause of the patient’s cardiomyopathy, or if the tachycardia is secondary to 
another cardiomyopathy of a different etiology. Arrhythmia-induced cardiomyopa-
thy has been reported with nearly all types of tachyarrhythmia and frequent ectopy, 
both supraventricular and ventricular [2]. Different types of tachyarrhythmias 
associated with arrhythmia-induced cardiomyopathy include atrial fibrillation 
(AF), atrial flutter, atrial tachycardia, reentrant supraventricular tachycardias, and 
ventricular tachycardia. Regardless of the type of arrhythmia, therapy to restore 
normal sinus rhythm or to slow the ventricular rate (or eliminate ectopy) usually 
result in an improvement in left ventricular function.
The incidence of arrhythmia-induced cardiomyopathy is unclear, but an associa-
tion between tachycardia and cardiomyopathy is well known. An insight into the 
prevalence of arrhythmia-induced cardiomyopathy can be derived from cohort 
studies. In one study of 1269 patients undergoing ablation for atrial flutter, 184 had 
reduced ejection fractions (<40 percent) at baseline [3]. In another study with a 
cohort of 625 patients undergoing catheter ablation for a variety of tachyarrhyth-
mias, tachycardia-induced cardiomyopathy was present in 2.7 percent (17 of 625 
patients) [4]. Similarly, in one cohort of 331 patients who had catheter ablation of 
incessant atrial tachycardia (AT), myocardial dysfunction was present in 9 percent 
of patients [5]. Additionally, the patients in the cohort with arrhythmia-induced 
cardiomyopathy were younger, predominantly male, and had continuous or very 
frequent paroxysmal tachycardia.
In general, chronic tachycardia eventually causes significant structural changes 
in the heart, including left ventricular dilatation and cellular morphologic changes. 
However, the exact mechanism by which tachycardia produces such changes is 
not well explained. Additionally, the morphologic and biochemical changes that 
result from arrhythmia-induced cardiomyopathy may produce electrophysiological 
abnormalities. Chronic tachycardia was associated with ventricular arrhythmias 
(including polymorphic ventricular tachycardia and sudden death) in a canine 
model which result from a prolongation in repolarization [6]. Many alterations in 
neurohumoral and cellular activation have been described in arrhythmia-induced 
cardiomyopathy patients, and several factors may contribute to the development of 
rate-related myocardial dysfunction. However, data supporting certain potential 
mechanisms are lacking, and it remains unclear whether such changes play an 
etiologic role or if they arise because of tachycardia.
The clinical presentation of arrhythmia-induced cardiomyopathy can vary and 
usually involves signs and/or symptoms related to HF (dyspnea, fatigue, orthopnea, 
PND, chest pain or discomfort, lower extremities edema), cardiac tachyarrhythmias 
(palpitations, lightheadedness, dizziness, anxiety, etc) or both. The approach to the 
patient with suspected arrhythmia-induced cardiomyopathy includes a thorough 
history and physical examination with appropriately selected tests to establish 
the diagnosis and assess acuity, severity, and etiology. All patients should have an 
electrocardiogram (ECG) to determine the cardiac rhythm and ventricular heart 
rate (Figure 2). There are no specific ECG findings that distinguish patients with 
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and without arrhythmia-induced cardiomyopathy, and the ECG findings will vary 
depending upon the underlying tachyarrhythmia. It is important to determine 
which is the primary pathology, the arrhythmia, or the cardiomyopathy. Usually, 
the diagnosis of arrhythmia-induced cardiomyopathy can only be made after a 
successful trial of therapy to slow down the ventricular rate or to restore sinus 
rhythm after excluding the other potential causes of cardiomyopathy. Patients with 
suspected arrhythmia-induced cardiomyopathy should have continuous cardiac 
monitoring for 24 to 48 hours and have non-invasive imaging to assess cardiac 
structure and function. A transthoracic echocardiogram (TTE) is the preferred 
modality for assessing cardiac structure and function for most patients due to 
its widespread availability and ease of performance. However, cardiac magnetic 
resonance (CMR) imaging is also a reasonable alternative approach in centers with 
expertise in this modality.
The initial treatments for a patient with HF and suspected arrhythmia-induced 
cardiomyopathy are similar to those of HF with reduced ejection fraction (HFrEF) 
and tachyarrhythmias. Treatment of HFrEF generally includes the use of angioten-
sin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), 
angiotensin receptor-neprilysin inhibitor (ARNI), beta-blockers, or diuretics. On 
the other hand, treatment of tachyarrhythmia includes rate-control medications, 
consideration of antiarrhythmic drugs, and/or cardioversion. Aggressive efforts 
should be made to achieve good ventricular heart rate control or to restore sinus 
rhythm due to the potentially reversible nature of arrhythmia-induced cardiomy-
opathy [2]. Additionally, an adequate trial of medical therapy is required before 
evaluating the patient for the need for cardiac resynchronization therapy (CRT) or 
an implantable cardioverter-defibrillator (ICD).
Following the restoration of sinus rhythm or appropriate ventricular rate 
control, most patients show significant improvement and/or normalization of left 
ventricular ejection fraction (LVEF) over a period of months. Generally, patients 
who have not experienced sudden cardiac arrest or sustained ventricular arrhyth-
mia and whose LVEF has improved to 40% or greater, do not require implantation 
of an ICD. If arrhythmia-induced cardiomyopathy recurs, then these patients are 
at substantial risk for sudden death and ICD implantation should be considered. 
Figure 2. 




In some patients, the LV chamber may remain somewhat enlarged even after LVEF 
has normalized. Patients will also have ultrastructural abnormalities of the myo-
cardium, despite improvement in cardiac function when a tachycardia has been 
terminated or rate controlled [7].
4. Alcoholic cardiomyopathy
Long-term excess alcohol consumption is a leading cause of secondary dilated 
cardiomyopathy and is associated with up to 40% of dilated cardiomyopathy. 
Alcohol use can cause atrial enlargement, global chamber dilation, cardiomegaly, 
and heart failure. Once the structural changes are present, patients with alcoholic 
cardiomyopathy are at high risk for arrhythmias, especially atrial fibrillation (AF). 
The prevalence of alcoholic cardiomyopathy is similar in men and women; however, 
there is a higher disease burden in men. It is more common in the age group of 
45–59 years old. Most patients who develop alcoholic cardiomyopathy have been 
drinking more than 80 to 90 g of ethanol per day for more than five years. This 
corresponds to approximately eight bottles of beer, one liter of wine, or one-half 
pint of hard liquor every day. The pathogenesis of alcoholic cardiomyopathy is not 
well understood, but experimental data have suggested that alcohol consumption 
may directly or indirectly cause oxidative stress, apoptosis, impaired mitochondrial 
bioenergetics, altered fatty acid metabolism, and increased myocardial protein 
catabolism via its metabolites. The pathophysiology of alcoholic cardiomyopathy 
can also be explained by myocardial toxicity due to adenosine accumulation caused 
by the impairment of ATP production secondary to thiamine deficiency (Thiamine 
serves as a co-factor for ATP production).
Common clinical features include classic symptoms of HF (dyspnea, fatigue, 
orthopnea, PND, chest pain or discomfort, lower extremities edema) and cardiac 
arrhythmias (palpitations, lightheadedness, dizziness, anxiety, etc). Patients may 
have a normal physical exam but can also have findings of heart failure such as the 
decreased intensity of the heart sounds, new S3 or S4 gallop, new murmurs due to 
valvular insufficiency, increased jugular venous pressure, hepatojugular reflux, 
and peripheral edema. An EKG usually does not show any specific findings, but 
may show atrial fibrillation, atrial enlargement, or left ventricular hypertrophy as 
the most common findings. The mainstay of treatment is abstinence from alcohol 
which can help in reversing the disease and management of HF. Thus, prognosis 
in such patients is usually good if they continue to avoid alcohol. If the patient 
does not stop drinking alcohol, the alcoholic cardiomyopathy may cause severe HF 
and could advance to severe valvular insufficiency, fatal arrhythmias, and sudden 
cardiac death.
5. Cardiomyopathy due to acute myocarditis
Myocarditis is a global cardiomyopathy that leads to acute chamber dilation. 
It is a major cause of death in young adults, reaching up to 20% of deaths. The 
incidence of myocarditis, according to the International Classification of Diseases’ 
diagnosis codes, was 22 patients per 100,000 patients in the 2013 world popula-
tion. Myocarditis is an inflammatory disease of the heart that may occur because 
of infections, immune system activation, or exposure to drugs. The common 
causes include coxsackievirus (most common), Lyme disease, Chagas disease [8], 
rheumatic fever, toxic (monoxide, diphtheria, doxorubicin, daunorubicin, cocaine) 
[9, 10], autoimmune or systemic diseases (SLE, sclerosis, sarcoidosis) [11]. Most 
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patients diagnosed with acute myocarditis recover without clinically relevant 
residual damage. Patients usually present with viral illness (Fever, malaise, fatigue, 
etc.) [12]. Patients can also present with symptoms of acute heart failure and 
conduction abnormalities (Premature atrial complex, supraventricular tachycardia, 
ventricular ectopies, bradyarrhythmia) including fatal arrhythmia (Ventricular 
tachycardia, fibrillation) leading to sudden cardiac death [13].
Common physical examination findings may include chest pain, new gal-
lop, friction rub, or new valvular insufficiency on auscultation; hepatomegaly, 
cardiogenic shock, tachypnea with or without respiratory distress [14]. The ECG 
in some patients with myocarditis is similar to the ECG pattern of acute isolated 
pericarditis (which is suggestive of myopericarditis) or acute MI, myocarditis 
may be associated with regional ST elevations and Q waves like acute MI [15]. 
Laboratory tests can reveal elevated levels of troponin, pro-BNP, and CK-MB [16]. 
Echocardiography can be useful by showing wall motion abnormalities and acute 
valvular insufficiency [17].
Coronary angiography should be considered in patients when acute coronary 
syndrome (ACS) cannot be distinguished from the myocarditis clinically [18]. CMR 
is indicated in patients with suspected myocarditis with elevated troponin level 
and/or ventricular dysfunction, without a clear cause such as ischemic heart disease 
[19]. The definitive diagnosis of myocarditis can be made by endomyocardial biopsy 
(EMB). The need for an EMB should be based upon the likelihood that the results 
will change management. Histologic examination of EMB in myocarditis reveals 
cellular infiltrates, which are usually histiocytic and mononuclear with or without 
associated myocyte damage; specific histological forms of myocarditis include 
eosinophilic, granulomatous, and giant cell myocarditis. Possible late complications 
include severe valvulopathies, biventricular failure, and conduction abnormalities 
[20]. The mainstay treatment is to treat the underlying cause. Most patients with 
acute myocarditis have partial or full clinical recovery. In some cases, the process 
may continue subclinically which eventually causes DCM [21]. The likelihood of 
these late complications is increased in patients who present with greatly dimin-
ished left ventricular function.
6. Sepsis-induced cardiomyopathy
Sepsis-induced cardiomyopathy is a reversible condition causing left ventric-
ular dilation that could lead to low filling pressures and low ejection fraction. 
It usually starts to normalize within 10 days of treatment of underlying sepsis 
[22]. Sepsis-induced myocardial dysfunction is one of the major predictors of 
morbidity and mortality in sepsis [23]. It is usually present in more than 40% 
of cases of sepsis and its presence can increase the mortality rate up to 70% 
[24, 25]. The exact physiopathology is not completely understood but the role 
of cytokines and endotoxins is thought to have an important role in the myo-
cardial depression found in this condition. Other factors that are also related 
are metabolic disturbances, hypoxia, coagulopathies, and oxygen deprivation 
leading to myocardial injury [26]. Another theory is the high consumption of 
oxygen by the mitochondria creating an energy imbalance. Pro-inflammatory 
factors from infectious agents cause a release of cytokines and endotoxins that 
accelerate the oxygen consumption in a low oxygen environment eventually 
leading to the production of e metabolites such as free radicals and nitrogen 
species [27]. These metabolites then create a toxic environment and a transient 
myocardial injury [28, 29]. Sepsis can also cause Takotsubo cardiomyopathy 




The clinical features include fever, elevated WBCs, weakness, and malaise along 
with clinical features of HF. Physical exam findings may include rash, conjunctivi-
tis, wounds, or evident infection. Patients may also present with hypotension, chest 
pain, or altered mental status. EKG usually does not show any specific findings, but 
may show findings suggestive of ACS due to underlying myocardial inflammation 
[30]. Laboratory tests may show elevated inflammatory markers, such as elevated 
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin due to 
systemic inflammation [31]. Additionally, cardiac markers may be also elevated due 
to underlying myocardial injury [32, 33]. Furthermore, cultures should be obtained 
to identify the causative agent before starting a patient on antibiotics. The treat-
ment mainly includes treatment of underlying sepsis and stabilization of the patient 
when they are hemodynamically unstable to avoid myocardial injury secondary to 
profound hypotension or arrhythmia. The prognosis of the patient usually varies 
depending on the severity of sepsis, but generally, the prognosis is reserved.
7. Stress cardiomyopathy or Takotsubo cardiomyopathy
Stress cardiomyopathy is also known as Takotsubo cardiomyopathy or broken 
heart syndrome, and the clinical presentation mimics acute myocardial infarction 
[34]. This condition is most common in post-menopausal women. The possible rea-
son for involvement in such a patient group could be explained by hypotheses dem-
onstrating a potential protective effect of estrogen in stress CM [35–37]. The patient 
with such type of cardiomyopathy should be treated as ACS until the obstructive 
coronary disease is ruled out by coronary angiography. The pathophysiology behind 
stress cardiomyopathy is not well understood [38], but the possible mechanism can 
be explained by the sudden release of catecholamine (Norepinephrine, epinephrine, 
and dopamine) [39, 40] that causes cardiac stunning by myocyte perfusion impair-
ment and lead to myocardial tissue edema, necrosis, and fibrosis [41].
The clinical features include anxiety, tachycardia, and chest pain which can 
mimic chest pain of acute MI. EKG may vary from ST segment elevation (most 
common finding), ST segment depression (less common), QT interval prolonga-
tion, T wave inversion, abnormal Q waves, and non-specific abnormalities. Serum 
cardiac troponin levels are elevated in most patients with stress CM, while creatine 
kinase (CK) levels are generally normal or mildly elevated. Furthermore, brain 
natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) levels are elevated 
in most patients with stress CM. Radionuclide myocardial perfusion imaging is 
generally not indicated in patients presenting with suspected stress cardiomyopathy 
since most have high-risk features for ACS and will require coronary angiography. 
Patients with suspected non-ST elevation ACS with low to intermediate-risk fea-
tures may undergo radionuclide myocardial perfusion imaging. An echocardiogram 
can show a decrease in LVEF and LV wall motion abnormalities (Figure 3). Patterns 
of LV wall motion abnormality in patients with stress-induced cardiomyopathy 
include the apical type (most common), and atypical variants including mid-
ventricular, basal, focal (limited to an isolated segment), and global types. CMR 
may be helpful in the diagnosis and evaluation of stress cardiomyopathy when the 
echocardiogram is technically suboptimal and/or there is coexistent coronary artery 
disease. Late gadolinium enhancement (LGE) on CMR is usually absent in stress 
cardiomyopathy in contrast to MI in which intense subendocardial or transmural 
LGE is seen.
Stress-induced cardiomyopathy is generally a reversible disorder that is man-
aged with supportive therapy [42]. Rapid resolution of symptoms can be usually 
seen with conservative treatment and resolution of the physical or emotional 
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stress. However, some patients may develop acute complications such as shock and 
acute HF that require intensive therapy. Appropriate management of shock varies 
and depends on whether significant left ventricular outflow tract (LVOT) obstruc-
tion is present [43]. HF management during an acute presentation and following 
stabilization is generally performed according to standard guidelines. However, 
caution should be performed to avoid volume depletion and with use of vasodila-
tor therapy in patients with LVOT obstruction. Recommendations for anticoagula-
tion to prevent thromboembolism in patients with stress cardiomyopathy with 
LV thrombus or severe LV systolic dysfunction are similar to those for post-MI 
patients [44, 45].
8. Peripartum cardiomyopathy
Peripartum cardiomyopathy is an important cause of dilated cardiomyopathy 
and HF. It is also known as pregnancy-associated cardiomyopathy [46]. The diagno-
sis can be missed due to the lack of regular screening and overlap between clinical 
signs or symptoms of HF signs or symptoms of the pregnancy [47]. Peripartum 
cardiomyopathy usually occurs during the last trimester or within the 6 months 
of the postpartum period. Several risk factors have been identified which include 
greater age, multiple gestations, African descent, and a history of preeclampsia, 
eclampsia, or postpartum hypertension. The pathophysiology is not clearly under-
stood but Honigberg and Givertz suggested the possible role of oxidative stress on 
myocardium caused by elevated prolactin levels [48].
The clinical features of peripartum cardiomyopathy are usually masked by 
signs and symptoms of pregnancy and are difficult to diagnose solely based on 
clinical findings. Patients usually present with similar clinical presentation as 
HF patients (shortness of breath, fatigue, orthopnea, lower extremities pitting 
edema). An echocardiogram is the modality of choice for definitive diagnosis 
of peripartum cardiomyopathy and usually shows dilated cardiomyopathy with 
an impairment of the ejection fraction [49]. Echocardiogram generally reveals 
a global reduction in LV systolic function with LVEF nearly always <45 percent. 
Management is similar to the treatment of HF with reduced EF, such as ACE 
inhibitors or ARBs or ARNI, beta-blockers, and diuretics. In addition to this treat-
ment, use of bromocriptine should also be considered [50]. However, prophylactic 
anticoagulation should always be considered along with bromocriptine treatment 
as thromboembolic events have been noticed during the use of bromocriptine [50]. 
Patients should get a repeat echocardiogram six weeks after diagnosis has been 
made for prognostication [51].
Figure 3. 




9. Thyroid disease induced cardiomyopathy
Metabolic cardiomyopathy is a secondary cardiomyopathy that results from 
disturbed energy production leading to impaired cardiac function. It may be caused 
by a myriad of endocrine disorders, nutritional deficiencies, and familial storage 
diseases [52]. Thyroid hormones have been shown to affect myocytes by acting 
on various thyroid hormone receptors in the myocardium, including a-myosin 
heavy chain fusion, sarcoplasmic reticulum calcium-activated ATPase (SERCA), 
the cellular membrane Na+/K+ pump (Na+/K+ ATPase), β-adrenergic receptors, 
cardiac troponin I, and atrial natriuretic peptide (ANP) [53]. These interactions 
help upregulate α-chains but downregulate β-chains in myocytes, which ultimately 
leads to faster myocardial fibril shortening [54]. Thyroid hormones have also been 
shown to affect the ion channels, including Na+/K+ ATPase, Na+/Ca + 2 exchanger, 
and various K+ channels by inducing positive inotropic effects, thereby prolong-
ing activation of Na + channels and shortening action potential durations [55]. 
Additionally, thyroid hormones have been known to have a vasodilatory effect 
on peripheral arteries [56]. The combined effort of these mechanisms can cause 
systemic changes in cardiac function by reducing peripheral vascular resistance, 
activating the renin-angiotensin mechanism, increasing LV end-diastolic volume 
(LVEDV), and increasing preload [57]. The increased preload and decreased 
peripheral vascular resistance lead to a high cardiac output, even at rest, resulting 
in cardiomyopathy. In contrast to hyperthyroidism, hypothyroidism causes a low 
cardiac output cardiomyopathy via the same pathways mentioned above, however, 
by downregulating the previously mentioned receptors/channels causing decreased 
myocardial excitation and contractility leading to a low-output cardiomyopathy 
[58]. The clinical features are similar to those seen in patients with HF.
Management of thyroid disease-induced cardiomyopathy follows a similar 
algorithm to the cardiomyopathies mentioned above, which includes the typical HF 
treatment regimen. Management also includes addressing the root etiology, whether 
it be excess or deficiency of thyroid hormones. However, there is promising data 
showing that the use of β-adrenergic blockade may be beneficial in these patients. 
Biondi et al. conducted a small study which demonstrated that hyperthyroid 
patients treated with the selective β1-adrenoceptor antagonist bisoprolol experi-
enced normalization of the LV mass index and LV systolic function after 6 months 
of treatment [59]. Similar results were established in a case study published a year 
later in which the use of β-adrenoceptor blockers showed clinical improvement in 
a patient with dilated cardiomyopathy caused by hyperthyroidism [60]. It is also 
worth mentioning the association between hyperthyroidism and AF. The preva-
lence of AF in thyrotoxicosis is estimated to be 13% according to one study. This 
is especially important as uncontrolled AF is associated with tachycardia-induced 
cardiomyopathy as discussed above. [61, 62]
10.  Cardiomyopathy related to obstructive sleep apnea or 
hypoventilation
Obstructive sleep apnea (OSA) is a potentially life-threatening condition that 
is characterized by repeated cessation of breathing while sleeping mostly due to 
complete or partial pharyngeal obstruction [63]. There has been evidence support-
ing the associations between obstructive sleep apnea and cardiovascular morbidity 
and mortality. The National Commission on sleep disorders research estimated that 
sleep apnea is probably responsible for 38,000 cardiovascular deaths per year [64]. 
Also, obstructive sleep apnea increases the risk of coronary artery disease by 30%, 
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heart failure by 140%, and stroke by 60% [65]. OSA can be identified by a combina-
tion of symptoms and laboratory results, such as repetitive apneas and hypopneas 
accompanied by hypoxia, sleep arousals, and hemodynamic changes [66–69]. 
Furthermore, activation of the sympathetic nervous system during respiratory 
events potentiates vasoconstriction and often triggers increases in blood pressure 
and heart rate [67, 70]. OSA is also associated with several cardiorespiratory prob-
lems such as loud snoring, loud gasps, and daytime breathlessness [71, 72].
The underlying mechanisms showing the associations between OSA and cardio-
vascular disease are not completely understood, but several intermediate mechanisms 
have been proposed. They include sustained sympathetic activation, changes in 
intrathoracic pressure and oxidative stress, and later vascular inflammation caused by 
nocturnal hypoxia and reoxygenation cycles [73, 74]. These mechanisms then results 
in increases in systolic blood pressure that might eventually lead to hypertension or 
worsening of this condition. A similar mechanism might explain the link between 
OSA and tachyarrhythmia [75]; whereas bradyarrhythmia, which is more common 
than tachyarrhythmia, might be the effect of an increase in vagal tone due to stimula-
tion of receptor sites in the upper airway [76]. Other abnormalities observed among 
patients with OSA such as disorders in coagulation factors, endothelial damage, 
platelet activation, and an increase in inflammatory mediators might also be involved 
in the pathogenesis of cardiovascular disease [74, 76–79]. Patients with OSA have char-
acteristically higher levels of endothelin and lower levels of nitric oxide than healthy 
sleepers [74, 77]. This increased endothelin level is known to impair blood pressure 
regulation as well. Thus, patients with OSA often experience greater blood vessel con-
striction. Interestingly, with continuous positive airway pressure (CPAP) treatment, 
levels of endothelin and circulating nitric oxide invariably return to normal [77].
Recently, research interests have centered on the relative contribution of oxida-
tive stress in explaining the associations between sleep apnea and cardiovascular 
morbidity [74, 79, 80]. Investigators have proposed that hypoxia, which is com-
monly observed in sleep apnea, promotes the formation of reactive oxygen species 
(ROS), which could activate the transcriptional activator hypoxia-inducible factor 
1 (HIF-1), particularly during the reoxygenation period [81, 82]. ROS regulates 
the activation of critical transcription factors that are redox-sensitive, resulting 
in increased expression of genes, which encode proteins promoting adaptation to 
hypoxia [81]. It has been suggested that redox-sensitive transcription factors, which 
elicit inflammatory pathways are also activated, thereby affecting inflammatory 
and immune responses by promoting activation of endothelial cells, leukocytes, 
and platelets [74]. These cells once activated can express adhesion molecules and 
proinflammatory cytokines that may lead to endothelial injury and dysfunc-
tion, which inevitably lead to the development of cardiovascular morbidity [74]. 
Observing this chain of events, investigators surmise that atherogenesis apparently 
starts soon after the onset of sleep apnea [74]. Substantial atherosclerotic insults are 
likely incurred by the time a diagnosis is rendered since symptoms often become 
apparent around the age of 45 years [74, 80]. It is unclear whether such atherogenic 
damages can be reversed, but treatment can retard their progress [83].
Using CPAP therapy, investigators have shown significant reductions in levels 
of C-reactive protein and interleukin-6 [83], and atherogenic plaque regression has 
been observed among patients with dyslipidemia [84]. Therefore, sleep apnea diag-
nosis and treatment should be made as early as possible in order to prevent cardio-
vascular morbidity. The use of CPAP or bilevel PAP therapy have showed positive 
benefits in clinical trials. This therapeutic modality is highly effective in improving 
left ventricular ejection fraction and quality of life by decreasing blood pressure and 
sympathetic activity and reducing mortality among patients with congestive heart 




cardiovascular death, and hospitalization for heart failure among patients with 
coronary artery disease [87]. Furthermore, CPAP therapy has significant effects on 
lipid levels. CPAP studies show significant improvement in insulin sensitivity and 
left ventricular function with a corresponding decrease in blood pressure [88].
11. Toxic cardiomyopathy
Dilated cardiomyopathy can result from direct exposure to toxins, such as 
cocaine, alcohol, medications, particularly chemotherapeutic drugs, and radiation 
in the absence of abnormal underlying cardiovascular conditions such as hyper-
tension, valvular disease, or coronary artery disease. The true prevalence of toxic 
cardiomyopathy in the general population is not known. The mechanism of toxic 
cardiomyopathy caused by some common toxic substances has been mentioned 
here. Alcoholic cardiomyopathy has been discussed separately. Patients with toxic 
cardiomyopathy usually present with clinical features similar to patients with 
systolic HF and the treatment involves the avoidance of toxic substances along with 
treatment for systolic HF.
11.1 Cocaine
Cocaine use is associated with the development of cardiomyopathy. However, 
the relationship is not well understood as compared to the relationship between 
cocaine use and coronary ischemia. Multiple mechanisms have been explained 
including the excessive sympathetic stimulation with increased myocardial oxygen 
consumption, direct toxic effect, and infectious cardiomyopathy in a parenteral 
cocaine user. In young persons, cardiomegaly with otherwise unexplained HF 
should raise the suspicion of cocaine abuse. Abstinence from cocaine usually leads 
to complete reversal of the myocardial dysfunction.
11.2 Medications
A number of medications such as anticancer drugs, anti-diabetic drugs, or 
antiretroviral drugs are associated with cardiomyopathy, and discontinuation of 
such drugs may result in significant improvement in cardiac function.
Anticancer drugs, such as anthracycline, trastuzumab, and cyclophosphamide 
are known to cause CM. Anthracycline-induced cardiomyopathy has been the most 
extensively studied. The mechanisms of anthracycline-induced cardiotoxicity are 
primarily due to its mechanisms of action as anticancer drugs which is inhibition of 
topoisomerase II β and DNA cleavage. Additionally, metabolic or oxidative stress fac-
tors may play a part, together with interference with iron metabolism. On the other 
hand, trastuzumab is a monoclonal antibody directed against the c-erbB-2 (HER2/
neu) receptor that is used in the treatment of breast cancer. Since the HER2 signal-
ing pathway plays an important role in cardiac development and protection, there 
is biological plausibility for cardiac toxicity with the use of trastuzumab [89, 90]. 
cardiomyopathy is also known to develop when a loss of function mutation occurs in 
HER2 in ventricular myocytes [91].
Antidiabetic medications such as thiazolidinedione class drugs are known to 
cause cardiotoxicity. The possible mechanisms of cardiotoxicity caused by these 
drugs include oxidative stress and interference with mitochondrial respiration. On 
the other hand, antiretroviral medications like azidothymidine are also cardiotoxic 
as a result of mitochondrial toxicity. Azidothymidine also increases the production 
of mitochondrial reactive oxygen species (ROS) in addition to energy depletion.
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11.3 Methamphetamine
Methamphetamine and related compounds are the second most widely used illicit 
drug in the United States after cannabis [92]. Methamphetamine-associated cardiomy-
opathy (MACM) may be seen in chronic methamphetamine users. The primary mecha-
nism of action of methamphetamine is the increased release and decreased uptake of 
catecholamines at the neuronal synapse producing a marked effect on the cardiovascu-
lar system [92]. The increased levels of catecholamines can stimulate alpha and beta-
adrenergic receptors leading to hypertension and tachycardia. Methamphetamine can 
lead to irreversible structural and functional changes in the heart which eventually lead 
to decompensated heart failure and ultimately requiring heart transplantation.
11.4 Carbon monoxide
Carbon monoxide (CO) exposure is known to cause cardiomyopathy by causing 
hypoxic injury. CO causes direct toxic damage to the mitochondria leading to an 
impairment of the mitochondrial respiratory chain at the cytochrome c oxidase 
level and a decrease of glutathione concentrations and ATP production. In survivors 
of an acute exposure, there is no evidence for a delayed dilated cardiomyopathy. 
In one retrospective study of 626 patients with CO exposure, only 3.04% (n = 19) 
patients had CO induced CM [93].
11.5 Trace elements
Trace elements are known to play an important role in myocardial metabolism 
and their accumulation (cobalt, arsenic) or deficiency (selenium) can be responsible 
for a form of dilated cardiomyopathy that is indistinguishable from an idiopathic 
CM. The role of trace elements was assessed in one study in which myocardial and 
skeletal muscle biopsies were obtained from 13 patients with an idiopathic DCM, 35 
patients with valvular or ischemic heart disease, and 4 normal subjects [94]. Patients 
with a dilated cardiomyopathy had a significant increase in the myocardial concen-
tration of mercury (22,000 times normal), antimony (12,000-fold higher), gold 
(11-fold higher), chromium (13-fold higher), and cobalt (4 times higher). On the 
other hand, patients with valvular or ischemic heart disease had myocardial concen-
trations of trace elements that were ≤ 5 times greater than normal. Concentrations 
of trace elements in skeletal muscle were normal in all groups of patients.
Cobalt-associated cardiomyopathy probably results from interference with 
energy production and contractile mechanisms. Cobalt associated cardiomyopathy 
has been reported in drinkers of beer containing cobalt sulfate for foam stabiliza-
tion (known as Quebec beer-drinkers’ cardiomyopathy) [95], individuals with 
work-related cobalt exposure, and in some individuals exposed to cobalt from metal 
hip prostheses [96]. There have been some reported cases where degeneration of 
metallic hip implants can lead to cobalt cardiomyopathy [97, 98]. Antimony may 
cause lethal oxidative stress and cell death mediated by elevation in intracellular cal-
cium. Proposed mechanisms for mercury toxicity include depletion of glutathione, 
ROS production and interruption in selenium-dependent endogenous enzymatic 
reactions. The existence of lithium-induced cardiomyopathy is still debated.
12. Uremic cardiomyopathy
Cardiovascular diseases are the leading cause of morbidity and mortality 




consequences are due to CKD related cardiomyopathy, which is termed uremic 
cardiomyopathy [100]. Uremic cardiomyopathy in patients with CKD or end-stage 
renal disease (ESRD) is the result of pressure overload, volume overload, and the 
uremic state itself. Epidemiological studies and studies using cardiac MRI have 
suggested that the primary manifestation of uremic cardiomyopathy is LV hyper-
trophy (LVH). It is present even in patients with very early stages of CKD. The 
prevalence of LVH in pre-dialysis patients is up to 65%. The pathogenesis of uremic 
cardiomyopathy is poorly understood and is generally multifactorial. Patients with 
CKD usually continue to have abnormal myocardial remodeling despite improve-
ments made to dialysis and advancements in the treatment of CKD, hypertension, 
hypervolemia, anemia. Two factors play an important role in the pathophysiology 
of patients with CKD and mineral and bone disease (CKD-MBD) which include the 
hormone FGF23, and its cofactor, αKlotho. FGF23 is deleterious to the myocardium, 
while αKlotho is protective. Although αKlotho is an obligatory cofactor for FGF23 
action as the primary phosphaturic hormone in phosphorus homeostasis, both 
factors are seen to have independent and antagonistic effects on the myocardium. 
Briefly, the main pathophysiology of uremic cardiomyopathy includes a triad of 
hyperphosphatemia, αKlotho deficiency, and elevated FGF23 levels [100].
The cause for very high cardiovascular risk in CKD patients can be explained 
by effects of traditional and non-traditional cardiovascular risk factors which are 
augmented by sequelae of CKD, such as uremia, anemia, hypervolemia, oxidative 
stress, inflammation, and insulin resistance eventually leading to faster progression 
of cardiovascular disease and increasing the number of cardiovascular events and 
mortality [101]. About 40% of deaths in dialysis patients are due to sudden cardiac 
death (SCD) which outweighs deaths due to HF, acute myocardial infarction (MI), 
and stroke in such population [102]. The major reason for sudden cardiac death in 
patients with uremic cardiomyopathy is fatal arrhythmia which is in contrast to 
the general population where the most common reason for SCD is acute MI. The 
risk factors for adverse cardiovascular events in dialysis patients include anemia, 
high parathyroid hormone levels, hypo or hypercalcemia, hyperphosphatemia, fast 
electrolyte shift, chronic volume overload, inflammation, coronary artery disease, 
autonomic dysfunction, atrial fibrillation, heart failure with systolic dysfunction, 
and left ventricular hypertrophy (LVH) [103].
The clinical features in uremic cardiomyopathy patients are similar to that of HF 
patients such as dyspnea, orthopnea, fatigue, weakness, elevated jugular venous 
pressure, an S3 gallop, rales, and peripheral edema. ECG can show findings sug-
gestive of LVH and may show nonspecific ischemic changes. Echocardiography 
may reveal LV systolic dysfunction, LV diastolic dysfunction, or valve dysfunction. 
Laboratory tests may show elevated natriuretic peptides and cardiac enzymes 
like other cardiomyopathies, but the interpretation of those tests is difficult in a 
patient with CKD or ESRD as these patients usually have elevated levels of cardiac 
biomarkers at baseline due to poor renal clearance. Thus, an entire clinical picture 
with lab tests, ECG findings, and echocardiogram findings should be taken to make 
a diagnosis of uremic cardiomyopathy.
Conventional hemodialysis is the main treatment for uremic cardiomyopathy, 
and it may cause regression of LVH. Hemodialysis is also known to reverse the 
systolic dysfunction and thus improve LVEF in some patients with ESRD. However, 
patients tend to continue to have cardiac dysfunction or uremic cardiomyopathy 
even while on hemodialysis treatment, thus conventional hemodialysis may not be 
adequate treatment despite being the treatment of choice. Renal transplantation has 
been shown to reverse uremic cardiomyopathy and to confer a significant survival 
advantage over hemodialysis [104]. Future therapies targeting the underlying 
cellular mechanisms of uremic cardiomyopathy may help to reduce the burden of 
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uremic cardiomyopathy in the CKD and ESRD population. In a study on uremic 
mice, Rapamycin has been shown to reduce cardiac hypertrophy and fibrosis [105]. 
Thus, rapamycin has the potential to be an effective therapy for uremic cardiomy-
opathy. LVH is the early and pertinent manifestation of uremic cardiomyopathy as 
well as a powerful independent predictor of survival in CKD. The regression of LVH 
can reduce cardiovascular risk and improve survival.
13. Cirrhotic cardiomyopathy
Cirrhotic cardiomyopathy (CCM) is defined as a cardiac dysfunction in patients 
with cirrhosis, which is characterized by impaired contractile responsiveness to 
stress and/or altered diastolic relaxation, with electrophysiological abnormalities, 
in the absence of other known cardiac disorder [106–108]. For years CCM was 
confused with alcoholic cardiomyopathy, but in 1953, Kowalski and Abelmann 
demonstrated the existence of a circulatory dysfunction specific to liver cirrhosis 
[109]. Since then many experimental and clinical studies have established the 
existence of CCM different than alcoholic cardiomyopathy. Cirrhosis of the liver 
leads to a hyperdynamic circulatory state, which induces cardiac dysfunctions 
that characterize the CCM syndrome which includes a combination of systolic and 
diastolic dysfunctions, prolonged ventricular repolarization, and the inability of the 
sinus node to increase heart rate during exercise [108].
CCM is a condition in which patients usually remain asymptomatic for months 
to years as they have a near-normal cardiac function at rest and develop symptoms 
only under conditions of physical or pharmacological stress [110]. Thus, the 
diagnosis of CCM is challenging and the actual prevalence of this condition remains 
unknown. Pathogenesis of CCM includes mechanisms such as the increased activity 
of the vasodilator pathway through the actions of NO, cytokines, cannabinoids, 
carbon monoxide, and cytokines, decreased beta-adrenergic function, and sodium 
and calcium transport kinetics downregulation in the cardiac muscle which can lead 
to an impaired contractile function of the cardiomyocyte. CCM is generally a silent 
condition as patients at rest do not develop any signs or symptoms of heart failure as 
peripheral vasodilatation protects the heart by reducing afterload [108]. However, 
CCM should be suspected in patients with cirrhosis presenting with a decrease in 
exercise tolerance and HF symptoms in the absence of any other underlying heart 
disease.
Echocardiogram and ECG are the most important tests to diagnose CCM. 
ECG can reveal prolongation of QT interval in such patients. The most common 
echocardiography finding in such patients is first-degree diastolic dysfunc-
tion which is characterized by reduced early diastolic ventricular filling and 
increased atrial filling (E/A < 1.0), deceleration time > 200 ms, and prolonged 
isovolumetric relaxation time (ITVR >80 ms) representing increased resistance 
to ventricular inflow [111]. Stress echocardiography is also a useful method that 
should be used in patients with advanced liver disease as it can detect subtle 
systolic and diastolic dysfunctions before the ventricular ejection fraction is 
decreased [112]. Laboratory tests usually show elevated levels of troponin, atrial 
natriuretic peptide (ANP), and NT-proBNP. Additionally, CMR can also serve 
as a useful tool in the diagnosis of CCM. In patients with CCM, late gadolinium 
enhancement has a diffuse myocardial distribution in MR images with the 
appearance of myocarditis [113].
The treatment of CCM is similar to the treatment of HF in non-cirrhotic 
patients. However, reduction in afterload is not recommended in patients with 




patients with final-stage liver disease and associated with CCM, liver transplanta-
tion is the only effective established treatment. Liver transplantation has been 
shown to reverse the systolic and diastolic dysfunction and prolonged QT interval 
[114, 115]. However, the unavailability of organ donors and cost concerns should 
be considered. The candidates must be well evaluated, as patients are at risk of 
death by HF, coronary artery disease, tachyarrhythmias, and other cardiac deaths 
in the post-operative term of liver transplantation. There is no accurate data on the 
prognosis for liver transplantation in patients with CCM. Patients with CCM should 
avoid physical effort and other forms of stress and should be provided with oxygen 
in some situations.
14. Conclusion
Reversible cardiomyopathies have been considered as one of the under diagnosed 
etiologies of non-ischemic cardiomyopathy that require careful clinical insight. 
Although reversible in nature but if remain undiagnosed, it can lead to catastrophic 
effects. It is hypothesized to have better prognosis compared to ischemic cardiomy-
opathy. Early diagnosis is warranted to guide efficient treatment. Further research 
regarding diagnostic and therapeutic algorithm for this subset of cardiomyopathy is 




Myocarditis Inflammation due to infectious agent, 
most commonly viral.
Natural course with recovery, no 
definitive treatment.
Steroid may be used in Giant cell 
myocarditis
Sepsis-induced Not well understood. Probably reaction 
due to cytokines release.
Treatment of underlying 
infection.
Alcoholic High incidence of cardiomegaly. Toxicity 
mediated due to adenosine accumulation.
Alcohol cessation
Peripartum Most commonly in the last trimester. 
Could be misdiagnosed. Not clear 
mechanism.
Standard CHF treatment. 
Bromocriptine may be helpful
Stress Induced Known as Takotsubo Cardiomyopathy. 
Caused by sudden release of 
catecholamine due to stress.
Spontaneous recovery





It is a part of Metabolic Cardiomyopathy. 
Caused by hyper or hypothyroidism. 
Could lead to arrhythmias especially atrial 
fibrillation.




Most commonly due to OSA. Could cause 
structure and hemodynamic changes.
Better prognosis if early 
intervention of the OSA before 
severe changes in the intracardiac 
pressures.
Toxic Could be cause by licit or ilicit agents that 
results cardiotoxic
Most of the times reversible once 
the agent is stopped.
Table 1. 
Summary of Reversible Cardiomyopathies.
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